Vertex Pharmaceuticals Incorporated, through its wholly owned subsidiary Adams Merger Sub, Inc., has announced a tender offer to acquire all issued and outstanding shares of Alpine Immune Sciences, Inc. at a price of $65.00 per share in cash. The offer, detailed in an amendment to the Schedule TO filed with the SEC on April 22, 2024, is set to expire at 11:59 p.m. ET on May 17, 2024, unless extended. The amendment supplements previous disclosures, including the expected filing of Premerger Notification and Report Forms under the HSR Act by April 24, 2024, and provides additional information on the background of the offer and regulatory approvals. The offer's terms and conditions, including the potential extension of the expiration time, are outlined in the Offer to Purchase. Vertex has also filed related materials with the SEC, including a press release and excerpts from their Q1 earnings call on May 6, 2024.

Vertex Pharmaceuticals Incorporated, through its wholly owned subsidiary Adams Merger Sub, Inc., has announced a tender offer to acquire all issued and outstanding shares of Alpine Immune Sciences, Inc. at a price of $65.00 per share in cash. The offer, detailed in an amendment to the Schedule TO filed with the SEC on April 22, 2024, is set to expire at 11:59 p.m. ET on May 17, 2024, unless extended. The amendment supplements previous disclosures, including the expected filing of Premerger Notification and Report Forms under the HSR Act by April 24, 2024, and provides additional information on the background of the offer and regulatory approvals. The offer's terms and conditions, including the potential extension of the expiration time, are outlined in the Offer to Purchase. Vertex has also filed related materials with the SEC, including a press release and excerpts from their Q1 earnings call on May 6, 2024.